Sorafenib induces apoptosis in HL60 cells by inhibiting Src kinase-mediated STAT3 phosphorylation

Anti-Cancer Drugs

Volumn 22, Issue 1, 2011, Pages 79-88

  Zhao, Wei ^a   Zhang, Tao ^a   Qu, Bingqian ^a   Wu, Xingxin ^a   Zhu, Xu ^a   Meng, Fanyu ^a   Gu, Yanhong ^a,b   Shu, Yongqian ^b   Shen, Yan ^a   Sun, Yang ^a   Xu, Qiang ^a  

^a NANJING UNIVERSITY   (China)

^b THE FIRST AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

Author keywords

acute myeloid leukemia; human acute myeloid leukemia cell line; signal transducer and activator of transcription 3; sorafenib; Src

Indexed keywords

PROTEIN BCL 2; PROTEIN MCL 1; PROTEIN TYROSINE KINASE; SORAFENIB; STAT3 PROTEIN;

APOPTOSIS; ARTICLE; CANCER INHIBITION; DEPOLARIZATION; DNA BINDING; DRUG EFFICACY; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; LEUKEMIA CELL LINE; MITOCHONDRION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION;

APOPTOSIS; BENZENESULFONATES; CELL CYCLE; CELL GROWTH PROCESSES; CELL LINE, TUMOR; CELL SURVIVAL; DNA, NEOPLASM; HL-60 CELLS; HUMANS; LEUKEMIA, MYELOID, ACUTE; MITOCHONDRIA; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-BCL-2; PYRIDINES; SRC-FAMILY KINASES; STAT3 TRANSCRIPTION FACTOR;

EID: 78650515800     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/CAD.0b013e32833f44fd     Document Type: Article

References (36)

1. Yu H, Jove R. The STATs of cancer - new molecular targets come of age. Nat Rev Cancer 2004; 4:97-105.
2. Bromberg J, Darnell JE Jr. The role of STATs in transcriptional control and their impact on cellular function. Oncogene 2000; 19:2468-2473.
3. Germain D, Frank DA. Targeting the cytoplasmic and nuclear functions of signal transducers and activators of transcription 3 for cancer therapy. Clin Cancer Res. 2007; 13:5665-5669.
4. Al Zaid Siddiquee K, Turkson J. STAT3 as a target for inducing apoptosis in solid and hematological tumors. Cell Res 2008; 18:254-267.
5. Buettner R, Mora LB, Jove R. Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention. Clin Cancer Res 2002; 8:945-954.
6. Xia Z, Baer MR, Block AW, Baumann H, Wetzler M. Expression of signal transducers and activators of transcription proteins in acute myeloid leukemia blasts. Cancer Res 1998; 58:3173-3180.
7. Benekli M, Xia Z, Donohue KA, Ford LA, Pixley LA, Baer MR, et al. Constitutive activity of signal transducer and activator of transcription 3 protein in acute myeloid leukemia blasts is associated with short diseasefree survival. Blood 2002; 99:252-257.
8. Schuringa JJ,Wierenga AT, KruijerW, Vellenga E. Constitutive Stat3, Tyr705, and Ser727 phosphorylation in acute myeloid leukemia cells caused by the autocrine secretion of interleukin-6. Blood 2000; 95:3765-3770.
9. Wetzler M, Brady MT, Tracy E, Li ZR, Donohue KA, O'Loughlin KL, et al. Arsenic trioxide affects signal transducer and activator of transcription proteins through alteration of protein tyrosine kinase phosphorylation. Clin Cancer Res 2006; 12:6817-6825.
10. Ozawa Y, Williams AH, Estes ML, Matsushita N, Boschelli F, Jove R, et al. Src family kinases promote AML cell survival through activation of signal transducers and activators of transcription (STAT). Leuk Res 2008; 32:893-903.
11. Thomas SM, Brugge JS. Cellular functions regulated by Src family kinases. Annu Rev Cell Dev Biol 1997; 13:513-609.
12. Zhang Y, Turkson J, Carter-Su C, Smithgall T, Levitzki A, Kraker A, et al. Activation of Stat3 in v-Src-transformed fibroblasts requires cooperation of Jak1 kinase activity. J Biol Chem 2000; 275:24935-24944.
13. Garcia R, Bowman TL, Niu G, Yu H, Minton S, Muro-Cacho CA, et al. Constitutive activation of Stat3 by the Src and JAK tyrosine kinases participates in growth regulation of human breast carcinoma cells. Oncogene 2001; 20:2499-2513.
14. Rahmani M, Davis EM, Bauer C, Dent P, Grant S. Apoptosis induced by the kinase inhibitor BAY 43-9006 in human leukemia cells involves downregulation of Mcl-1 through inhibition of translation. J Biol Chem 2005; 280:35217-35227.
15. Lierman E, Folens C, Stover EH, Mentens N, Van Miegroet H, Scheers W, et al. Sorafenib is a potent inhibitor of FIP1L1-PDGFRalpha and the imatinib-resistant FIP1L1-PDGFRalpha T674I mutant. Blood 2006; 108:1374-1376.
16. Zhang W, Konopleva M, Shi YX, McQueen T, Harris D, Ling X, et al. Mutant FLT3: A direct target of sorafenib in acute myelogenous leukemia. J Natl Cancer Inst 2008; 100:184-198.
17. Rahmani M, Nguyen TK, Dent P, Grant S. The multikinase inhibitor sorafenib induces apoptosis in highly imatinib mesylate-resistant bcr/abl + human leukemia cells in association with signal transducer and activator of transcription 5 inhibition and myeloid cell leukemia-1 down-regulation. Mol Pharmacol 2007; 72:788-795.
18. Zhang W, Konopleva M, Ruvolo VR, McQueen T, Evans RL, Bornmann WG, et al. Sorafenib induces apoptosis of AML cells via Bim-mediated activation of the intrinsic apoptotic pathway. Leukemia 2008; 22:808-818.
19. Homsi J, Cubitt C, Daud A. The Src signaling pathway: A potential target in melanoma and other malignancies. Expert Opin Ther Targets 2007; 11:91-100.
20. Raje N, Kumar S, Hideshima T, Ishitsuka K, Chauhan D, Mitsiades C, et al. Combination of the mTOR inhibitor rapamycin and CC-5013 has synergistic activity in multiple myeloma. Blood 2004; 104:4188-4193.
21. Zhang B, Shi ZL, Liu B, Yan XB, Feng J, Tao HM. Enhanced anticancer effect of gemcitabine by genistein in osteosarcoma: The role of Akt and nuclear factor-kappaB. Anticancer Drugs 2010; 21:288-296.
22. Dai Y, Grant S. The histone deacetylase inhibitor sodium butyrate interacts synergistically with phorbol myristate acetate (PMA) to induce mitochondrial damage and apoptosis in human myeloid leukemia cells through a tumor necrosis factor-alpha-mediated process. Exp Cell Res 2002; 277:31-47.
23. Aggarwal BB, Sethi G, Ahn KS, Sandur SK, Pandey MK, Kunnumakkara AB, et al. Targeting signal-transducer-and-activator-of-transcription-3 for prevention and therapy of cancer: Modern target but ancient solution. Ann N Y Acad Sci 2006; 1091:151-169.
24. Flaherty KT. Sorafenib in renal cell carcinoma. Clin Cancer Res 2007; 13:747s-752s.
25. Spinzi G, Paggi S. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359:2497-2498.
26. Dowlati A, Kluge A, Nethery D, Halmos B, Kern JA. SCH66336, inhibitor of protein farnesylation, blocks signal transducer and activators of transcription 3 signaling in lung cancer and interacts with a small molecule inhibitor of epidermal growth factor receptor/human epidermal growth factor receptor 2. Anticancer Drugs 2008; 19:9-16.
27. Ulivi P, Arienti C, Amadori D, Fabbri F, Carloni S, Tesei A, et al. Role of RAF/MEK/ERK pathway, p-STAT-3 and Mcl-1 in sorafenib activity in human pancreatic cancer cell lines. J Cell Physiol 2009; 220:214-221.
28. Delgado JS, Mustafi R, Yee J, Cerda S, Chumsangsri A, Dougherty U, et al. Sorafenib triggers antiproliferative and pro-apoptotic signals in human esophageal adenocarcinoma cells. Dig Dis Sci 2008; 53: 3055-3064.
29. Yang F, Van Meter TE, Buettner R, Hedvat M, Liang W, Kowolik CM, et al. Sorafenib inhibits signal transducer and activator of transcription 3 signaling associated with growth arrest and apoptosis of medulloblastomas. Mol Cancer Ther 2008; 7:3519-3526.
30. Blechacz BR, Smoot RL, Bronk SF, Werneburg NW, Sirica AE, Gores GJ. Sorafenib inhibits signal transducer and activator of transcription-3 signaling in cholangiocarcinoma cells by activating the phosphatase shatterproof 2. Hepatology 2009; 50:1861-1870.
31. Drexler HG, Zaborski M, Quentmeier H. Thrombopoietin supports the continuous growth of cytokine-dependent human leukemia cell lines. Leukemia 1997; 11:541-551.
32. Turkson J, Bowman T, Garcia R, Caldenhoven E, De Groot RP, Jove R. Stat3 activation by Src induces specific gene regulation and is required for cell transformation. Mol Cell Biol 1998; 18: 2545-2552.
33. Zhao W, Gu YH, Song R, Qu BQ, Xu Q. Sorafenib inhibits activation of human peripheral blood T cells by targeting LCK phosphorylation. Leukemia 2008; 22:1226-1233.
34. Yu C, Bruzek LM, Meng XW, Gores GJ, Carter CA, Kaufmann SH, et al. The role of Mcl-1 downregulation in the proapoptotic activity of the multikinase inhibitor BAY 43-9006. Oncogene 2005; 24:6861-6869.
35. Lund TC, Coleman C, Horvath E, Sefton BM, Jove R, Medveczky MM, et al. The Src-family kinase Lck can induce STAT3 phosphorylation and DNA binding activity. Cell Signal 1999; 11:789-796.
36. Talpaz M, Shah NP, Kantarjian H, Donato N, Nicoll J, Paquette R, et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med 2006; 354:2531-2541.